HealthEquity, Inc. (HQY) Hit a 52 Week High, Can the Run Continue?
https://www.zacks.com/stock/news/2216440/healthequity-inc-hqy-hit-a-52-week-high-can-the-run-continue?cid=CS-ZC-FT-52_week_high-2216440
Jan 26, 2024 - HealthEquity (HQY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
0
Penumbra (PEN) Rides on Vascular Arm Strength Amid FX Woes
https://www.zacks.com/stock/news/2212281/penumbra-pen-rides-on-vascular-arm-strength-amid-fx-woes?cid=CS-ZC-FT-analyst_blog|zer_report_update-2212281
Jan 18, 2024 - Penumbra's (PEN) Vascular business is demonstrating strong growth, banking on a rapid increase in sales of vascular thrombectomy products in the United States.
0
Here's Why Investors Should Retain ResMed (RMD) Stock for Now
https://www.zacks.com/stock/news/2211621/here-s-why-investors-should-retain-resmed-rmd-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2211621
Jan 17, 2024 - Investors are optimistic about ResMed (RMD) on strong uptake of the myAir app with AirSense11.
0
Abbott's (ABT) Innovations Aid, Macroeconomic Issues Stay
https://www.zacks.com/stock/news/2211543/abbott-s-abt-innovations-aid-macroeconomic-issues-stay?cid=CS-ZC-FT-analyst_blog|zer_report_update-2211543
Jan 17, 2024 - Abbott (ABT) is successfully continuing the rollout of Alinity, the company's fully integrated and automated molecular diagnostics analyzer.
0
Here's Why Investors Should Retain Bruker (BRKR) Stock Now
https://www.zacks.com/stock/news/2210890/here-s-why-investors-should-retain-bruker-brkr-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2210890
Jan 16, 2024 - Investors are optimistic about Bruker (BRKR) on solid prospects of BSI Nano group and raised guidance.
0
Quest Diagnostics (DGX) Inks New Deal With Ultima Genomics
https://www.zacks.com/stock/news/2209990/quest-diagnostics-dgx-inks-new-deal-with-ultima-genomics?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2209990
Jan 15, 2024 - Quest Diagnostics' (DGX) new partnership is likely to leverage its oncology expertise and national scale.
0
Here's Why You Should Buy Align Technology (ALGN) Stock Now
https://www.zacks.com/stock/news/2209986/here-s-why-you-should-buy-align-technology-algn-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2209986
Jan 15, 2024 - Investors remain optimistic about Align Technology (ALGN) due to the progress in the Invisalign portfolio and highly favorable solvency.
0
Here's Why You Should Retain Charles River (CRL) Stock Now
https://www.zacks.com/stock/news/2209712/here-s-why-you-should-retain-charles-river-crl-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2209712
Jan 12, 2024 - Investors are optimistic about Charles River (CRL) owing to growth in the RMS and DSA segments and stable solvency position.
0
QIAGEN (QGEN) Wins FDA Clearance for NeuMoDx CT/NG Assay
https://www.zacks.com/stock/news/2209391/qiagen-qgen-wins-fda-clearance-for-neumodx-ct-ng-assay?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2209391
Jan 12, 2024 - QIAGEN (QGEN) receives FDA clearance for the NeuMoDx CT/NG Assay for use on both NeuMoDx 96 and 288 versions of the integrated PCR-based clinical molecular testing system.
0
LabCorp (LH) to Expand Clinical Trails Access With New Pact
https://www.zacks.com/stock/news/2208988/labcorp-lh-to-expand-clinical-trails-access-with-new-pact?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2208988
Jan 11, 2024 - LabCorp (LH) and Hawthorne Effect hope to enhance decentralized clinical trials by merging existing services and developing fresh, unique service offers.
0